Property:Outcome name
This is a property of type Text.
The allowed values for this property are:
- Additional medication
- Anorexia/Cachexia
- Antibodies
- Anxiety
- Appetite
- Arterial inflow
- BMD (Bone Mineral Density)
- Body composition
- Carnitine level
- Carotenoid concentration
- Cerebral oedema
- CINV (Chemotherapy-Induced Nausea and Vomiting)
- Cognitive functioning
- Cognitive impairment
- Depression
- Dermatitis
- DFS (Disease-Free Survival)
- Diarrhoe
- Distress
- Dysgeusia
- Ejection fraction
- Erectile dysfunction
- Erythema
- Esophagitis
- Fatigue
- Fever
- Fibrosis
- Folic acid level
- Functionality
- Haematological indices
- Haematological toxicity
- Hand-foot syndrome
- Hand grip strength
- Hormone level
- Incidence of acute GVHD (Graft-Versus-Host Disease)
- Infection
- Interaction with cancer treatment
- Ileus (intestinal obstruction)
- Laboratory parameters
- Length of hospital stay
- Lymphedema
- Menopausal symptoms
- Mental status/ function
- Mood/Affect
- Mortality rate
- Mucositis
- Musculoskeletal symptoms
- Nausea
- Nausea and Vomiting
- Nerve conduction velocity
- Neurotoxicity
- Neutropenia
- Non-haematological indices
- Nutrition status
- Objective signs and subjective symptoms
- Oral ulcus
- OS (Overall Survival)
- Ototoxicity
- Pain
- PD (Pharmacodynamics)
- Performance Status
- Peripheral neuropathy
- PFS (Progression-Free Survival)
- Pharyngitis
- Physical functioning
- PK (Pharmacokinetics)
- Postoperative morbidity/ complications
- PSA level (Prostate-Specific Antigen)
- Quality of life
- Recurrence rate
- REE (Resting Energy Expenditure)
- Relaxation
- RFS (Recurrence-Free Survival)
- Salivary gland function
- Seroconversion
- Selenium level
- Sleep
- Stomatitis
- Stress
- Symptom load
- Taste alteration
- Tea polyphenol uptake
- Thromboembolic event rates
- Toxicity
- Treatment interruption
- Tumor progression
- Tumor response
- Vaginal atrophy
- Vitamin A level
- Vitamin B6 level
- Vitamin B12 level
- Vitamin B17 level
- Vitamin C level
- Vitamin D level
- Vitamin E level
- Vomiting
- Weight
- Well-being
- Wound healing
- Wound odour
- Xerostomia
- Zinc level
- Unspecified effects
- NI
- ?
V
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
Tumor progression +
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
PFS (Progression-Free Survival) +
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
OS (Overall Survival) +
Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial +
Ototoxicity +
Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy +
Peripheral neuropathy +
W
Walsh et al. (2010): Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma +
DFS (Disease-Free Survival) +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Xerostomia +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Nutrition status +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Tumor response +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Pain +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Mucositis +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Taste alteration +
Wrbka et al. (1987): Unterstützung der Chemotherapie inoperabler Karzinome durch proteolytische Fermente +
Tumor response +
Wrbka et al. (1987): Unterstützung der Chemotherapie inoperabler Karzinome durch proteolytische Fermente +
Tumor response +
Wrbka et al. (1987): Unterstützung der Chemotherapie inoperabler Karzinome durch proteolytische Fermente +
Quality of life +
Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer +
Quality of life +
Showing 1 related entity.
{ "type": "PROPERTY_CONSTRAINT_SCHEMA", "constraints": { "type_constraint": "_txt", "allowed_values": [ "Anorexia/Cachexia", "Anxiety", "Appetite", "Cerebral oedema", "Cognitive functioning", "Cognitive impairment", "Depression", "Dermatitis", "Distress", "Dysgeusia", "Ejection fraction", "Erectile dysfunction", "Fatigue", "Haematological toxicity", "Hand-foot syndrome", "Ileus (intestinal obstruction)", "Lymphedema", "Menopausal symptoms", "Mood/Affect", "Mucositis", "Nausea", "Nausea and Vomiting", "Neutropenia", "Ototoxicity", "Pain", "Quality of life", "Recurrence rate", "Relaxation", "Stress", "Toxicity", "Vaginal atrophy", "Vomiting", "Weight", "Well-being", "Wound healing", "Xerostomia", "?", "NI", "Esophagitis", "Seroconversion", "Antibodies", "Carnitine level", "Folic acid level", "Haematological indices", "Incidence of acute GVHD (Graft-Versus-Host Disease)", "Length of hospital stay", "Mortality rate", "Non-haematological indices", "Performance Status", "Selenium level", "Tumor response", "Vitamin A level", "Vitamin B6 level", "Vitamin B12 level", "Vitamin B17 level", "Vitamin C level", "Vitamin D level", "Vitamin E level", "Zinc level", "OS (Overall Survival)", "Body composition", "Diarrhoe", "Nutrition status", "PSA level (Prostate-Specific Antigen)", "Taste alteration", "Tumor progression", "DFS (Disease-Free Survival)", "PFS (Progression-Free Survival)", "RFS (Recurrence-Free Survival)", "Carotenoid concentration", "Pharyngitis", "CINV (Chemotherapy-Induced Nausea and Vomiting)", "Fibrosis", "Functionality", "Hand grip strength", "Hormone level", "Musculoskeletal symptoms", "Objective signs and subjective symptoms", "Salivary gland function", "Thromboembolic event rates", "Wound odour", "BMD (Bone Mineral Density)", "PD (Pharmacodynamics)", "Sleep", "Tea polyphenol uptake", "Unspecified effects", "Peripheral neuropathy", "PK (Pharmacokinetics)", "Arterial inflow", "Erythema", "Laboratory parameters", "Mental status/ function", "Neurotoxicity", "Oral ulcus", "Physical functioning", "Additional medication", "Interaction with cancer treatment", "REE (Resting Energy Expenditure)", "Treatment interruption", "Fever", "Infection", "Nerve conduction velocity", "Postoperative morbidity/ complications", "Stomatitis", "Symptom load" ] } }